{"transactions":[{"id":4630735,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-10-05T21:12:51.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":4126,"price":57.1,"value":235594.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001838139-26-000028","document":"wk-form4_1791234769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1838139/000183813926000028/wk-form4_1791234769.xml","form_type":"4"}},{"id":4634554,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-10-01T00:32:14.000Z","date":"2026-09-28","kind":"sale","planned":true,"acquired":false,"shares":4126,"price":57.88,"value":238812.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026."}],"balance_after":4126,"source":{"system":"sec-edgar","filing":"0001838139-26-000026","document":"wk-form4_1790800331.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000026/wk-form4_1790800331.xml","form_type":"4"}},{"id":693124,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2026-08-07T21:11:13.000Z","date":"2026-08-07","kind":"gift","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":244412,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001838139-26-000024","document":"wk-form4_1786137071.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000024/wk-form4_1786137071.xml","form_type":"4"}},{"id":693123,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:11:13.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":8252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":8252,"source":{"system":"sec-edgar","filing":"0001838139-26-000024","document":"wk-form4_1786137071.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000024/wk-form4_1786137071.xml","form_type":"4"}},{"id":718147,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-07-02T20:10:26.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":9099,"price":55.8802,"value":508453.9398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.69 to $56.14 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001838139-26-000022","document":"wk-form4_1783023023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000022/wk-form4_1783023023.xml","form_type":"4"}},{"id":726416,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-06-25T21:13:55.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":9098,"price":55.1843,"value":502066.7614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.77 to $55.31 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9099,"source":{"system":"sec-edgar","filing":"0001838139-26-000020","document":"wk-form4_1782422032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000020/wk-form4_1782422032.xml","form_type":"4"}},{"id":768085,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-22T01:20:12.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":13684,"price":52.7505,"value":721837.842,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.62 to $52.96 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":18197,"source":{"system":"sec-edgar","filing":"0001838139-26-000018","document":"wk-form4_1779412810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000018/wk-form4_1779412810.xml","form_type":"4"}},{"id":777110,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-15T20:38:40.000Z","date":"2026-05-14","kind":"sale","planned":true,"acquired":false,"shares":13684,"price":53.0647,"value":726137.3548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.88 to $53.25 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31881,"source":{"system":"sec-edgar","filing":"0001838139-26-000016","document":"wk-form4_1778877517.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000016/wk-form4_1778877517.xml","form_type":"4"}},{"id":786925,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:10:50.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":18197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":45565,"source":{"system":"sec-edgar","filing":"0001838139-26-000014","document":"wk-form4_1778274645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000014/wk-form4_1778274645.xml","form_type":"4"}},{"id":905317,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:02:26.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":19970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":27368,"source":{"system":"sec-edgar","filing":"0001838139-26-000012","document":"wk-form4_1771016542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000012/wk-form4_1771016542.xml","form_type":"4"}},{"id":925352,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-02T21:59:30.000Z","date":"2026-01-30","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":41.0905,"value":821810.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.28 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001838139-26-000010","document":"wk-form4_1770069566.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000010/wk-form4_1770069566.xml","form_type":"4"}},{"id":931202,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-26T21:10:58.000Z","date":"2026-01-23","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":40.2555,"value":805110.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.56 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001838139-26-000008","document":"wk-form4_1769461855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000008/wk-form4_1769461855.xml","form_type":"4"}},{"id":935436,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-20T22:00:25.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":39.5173,"value":790346.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.37 to $39.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001838139-26-000006","document":"wk-form4_1768946423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000006/wk-form4_1768946423.xml","form_type":"4"}},{"id":940107,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-13T22:37:44.000Z","date":"2026-01-09","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":40.7817,"value":815634.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.57 to $40.97 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001838139-26-000004","document":"wk-form4_1768343862.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000004/wk-form4_1768343862.xml","form_type":"4"}},{"id":946900,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-06T21:17:52.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":38.4825,"value":769650.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.32 to $38.70 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001838139-26-000002","document":"wk-form4_1767734270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813926000002/wk-form4_1767734270.xml","form_type":"4"}},{"id":958248,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-29T21:58:27.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":39.319,"value":786380.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.22 to $39.41 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001838139-25-000014","document":"wk-form4_1767045504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000014/wk-form4_1767045504.xml","form_type":"4"}},{"id":961054,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-22T21:09:42.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":38.3791,"value":767582.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.22 to $38.57 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001838139-25-000012","document":"wk-form4_1766437779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000012/wk-form4_1766437779.xml","form_type":"4"}},{"id":965122,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-17T22:43:16.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":38.321,"value":766420.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.24 to $38.40 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":140000,"source":{"system":"sec-edgar","filing":"0001838139-25-000010","document":"wk-form4_1766011394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000010/wk-form4_1766011394.xml","form_type":"4"}},{"id":976266,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-09T22:00:36.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":18242,"price":39.1527,"value":714223.5534,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7398,"source":{"system":"sec-edgar","filing":"0001838139-25-000008","document":"wk-form4_1765317633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000008/wk-form4_1765317633.xml","form_type":"4"}},{"id":976265,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-09T22:00:36.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":23334,"price":39.1528,"value":913591.4352,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.32 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":160000,"source":{"system":"sec-edgar","filing":"0001838139-25-000008","document":"wk-form4_1765317633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000008/wk-form4_1765317633.xml","form_type":"4"}},{"id":981667,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:10:29.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":18242,"price":39.9,"value":727855.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.60 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":25640,"source":{"system":"sec-edgar","filing":"0001838139-25-000006","document":"wk-form4_1764799826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000006/wk-form4_1764799826.xml","form_type":"4"}},{"id":981666,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-12-03T22:10:29.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":23333,"price":39.9277,"value":931633.0241,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.72 to $40.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":183334,"source":{"system":"sec-edgar","filing":"0001838139-25-000006","document":"wk-form4_1764799826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000006/wk-form4_1764799826.xml","form_type":"4"}},{"id":1004924,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2025-11-07T21:16:29.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":247412,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001838139-25-000004","document":"wk-form4_1762550186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000004/wk-form4_1762550186.xml","form_type":"4"}},{"id":1004923,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-07T21:16:29.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":206667,"source":{"system":"sec-edgar","filing":"0001838139-25-000004","document":"wk-form4_1762550186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000004/wk-form4_1762550186.xml","form_type":"4"}},{"id":1004922,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-07T21:16:29.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":4626,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":43882,"source":{"system":"sec-edgar","filing":"0001838139-25-000004","document":"wk-form4_1762550186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000183813925000004/wk-form4_1762550186.xml","form_type":"4"}},{"id":1071415,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2025-08-08T20:52:53.000Z","date":"2025-08-08","kind":"gift","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":263412,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001802768-25-000101","document":"wk-form4_1754686370.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000101/wk-form4_1754686370.xml","form_type":"4"}},{"id":1071414,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-08-08T20:52:53.000Z","date":"2025-08-06","kind":"grant","planned":false,"acquired":true,"shares":2772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":39256,"source":{"system":"sec-edgar","filing":"0001802768-25-000101","document":"wk-form4_1754686370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000101/wk-form4_1754686370.xml","form_type":"4"}},{"id":1140527,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class E Ordinary Shares","published_at":"2025-05-20T20:54:04.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":1356528,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote (1)(2)"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares (\"Class E Shares\") of Royalty Pharma Holdings Ltd (\"RPH\") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the \"Purchase Agreement\") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion."}],"balance_after":1356528,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1356528},"source":{"system":"sec-edgar","filing":"0001802768-25-000069","document":"wk-form4_1747774436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000069/wk-form4_1747774436.xml","form_type":"4"}},{"id":1153817,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2025-05-09T21:07:47.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":36484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":83151,"source":{"system":"sec-edgar","filing":"0001802768-25-000031","document":"wk-form4_1746824860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000031/wk-form4_1746824860.xml","form_type":"4"}},{"id":1436061,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2024-08-12T23:17:16.000Z","date":"2024-08-12","kind":"gift","planned":false,"acquired":false,"shares":2182,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sandy Lamm LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":126412,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":21820},"source":{"system":"sec-edgar","filing":"0001802768-24-000047","document":"wk-form4_1723504630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000047/wk-form4_1723504630.xml","form_type":"4"}},{"id":1993448,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2023-02-24T23:26:24.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":23333,"price":37.2965,"value":870239.2345,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.19 to $37.56 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46667,"source":{"system":"sec-edgar","filing":"0001209191-23-012883","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123012883/doc4.xml","form_type":"4"}},{"id":2007878,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2023-02-17T21:57:12.000Z","date":"2023-02-17","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person has agreed to retain and not sell 128,594 RPI US LP Interests convertible into 1,285,940 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":128594,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-23-010715","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123010715/doc4.xml","form_type":"4"}},{"id":2007877,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2023-02-17T21:57:12.000Z","date":"2023-02-17","kind":"exercise","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001209191-23-010715","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123010715/doc4.xml","form_type":"4"}},{"id":2201374,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2022-07-27T22:17:27.000Z","date":"2022-07-26","kind":"sale","acquired":false,"shares":19734,"price":43.1976,"value":852461.4384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.38 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-043282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122043282/doc4.xml","form_type":"4"}},{"id":2201373,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2022-07-27T22:17:27.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":3600,"price":43.0514,"value":154985.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19734,"source":{"system":"sec-edgar","filing":"0001209191-22-043282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122043282/doc4.xml","form_type":"4"}},{"id":2222137,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2022-06-24T21:19:48.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":23333,"price":43.1875,"value":1007693.9375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.27 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23334,"source":{"system":"sec-edgar","filing":"0001209191-22-039294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122039294/doc4.xml","form_type":"4"}},{"id":2270447,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2022-05-16T23:14:30.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":23333,"price":39.8507,"value":929836.3831,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.09 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46667,"source":{"system":"sec-edgar","filing":"0000899243-22-018222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322018222/doc4.xml","form_type":"4"}},{"id":2274880,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-05-11T21:20:38.000Z","date":"2022-05-11","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person has agreed to retain and not sell 198,594 RPI US LP Interests convertible into 1,985,940 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":205594,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-22-017656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322017656/doc4.xml","form_type":"4"}},{"id":2274879,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Research & Investments"}}],"security":"Class A Ordinary Shares","published_at":"2022-05-11T21:20:38.000Z","date":"2022-05-11","kind":"exercise","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0000899243-22-017656","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322017656/doc4.xml","form_type":"4"}},{"id":2677818,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head of R&I"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-09T00:15:50.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":16568,"price":47.0219,"value":779058.8392,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950103-21-008573","document":"dp152447_4-urist.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008573/dp152447_4-urist.xml","form_type":"4"}},{"id":2677817,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head of R&I"}}],"security":"Class A Ordinary Shares","published_at":"2021-06-09T00:15:50.000Z","date":"2021-06-04","kind":"sale","acquired":false,"shares":16566,"price":45.1323,"value":747661.6818,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16568,"source":{"system":"sec-edgar","filing":"0000950103-21-008573","document":"dp152447_4-urist.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008573/dp152447_4-urist.xml","form_type":"4"}},{"id":2681110,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head Research & Inv."}}],"security":"Class A Ordinary Shares","published_at":"2021-06-04T22:52:12.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":14566,"price":41.5248,"value":604850.2368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $41.86 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":33134,"source":{"system":"sec-edgar","filing":"0000950103-21-008458","document":"dp152317_4-urist.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321008458/dp152317_4-urist.xml","form_type":"4"}},{"id":2699147,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head Research & Inv."}}],"security":"Class A Ordinary Shares","published_at":"2021-05-25T00:10:50.000Z","date":"2021-05-21","kind":"sale","acquired":false,"shares":100,"price":41,"value":4100.0,"ownership":{"direct":true},"balance_after":47700,"source":{"system":"sec-edgar","filing":"0000950103-21-007749","document":"dp151622_4-urist.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007749/dp151622_4-urist.xml","form_type":"4"}},{"id":2699146,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head Research & Inv."}}],"security":"Class A Ordinary Shares","published_at":"2021-05-25T00:10:50.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":1900,"price":41.0837,"value":78059.03,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.20 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47800,"source":{"system":"sec-edgar","filing":"0000950103-21-007749","document":"dp151622_4-urist.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007749/dp151622_4-urist.xml","form_type":"4"}},{"id":2718834,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head Research & Inv."}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-05-12T01:08:07.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":4970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person has agreed to retain and not sell 142,594 RPI US LP Interests convertible into 1,425,940 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":142594,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":49700},"source":{"system":"sec-edgar","filing":"0000950103-21-007079","document":"dp150862_4-urist.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007079/dp150862_4-urist.xml","form_type":"4"}},{"id":2718833,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25464,"kind":"person","name":"Urist Marshall","position":1,"cik":"0001838139","reported_name":"Urist Marshall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Co-Head Research & Inv."}}],"security":"Class A Ordinary Shares","published_at":"2021-05-12T01:08:07.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":49700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":49700,"source":{"system":"sec-edgar","filing":"0000950103-21-007079","document":"dp150862_4-urist.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007079/dp150862_4-urist.xml","form_type":"4"}}]}